5-chloro-2-fluoro-1-methoxy-3-(methylsulfinyl)benzene | 1452479-03-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-2-fluoro-1-methoxy-3-(methylsulfinyl)benzene
• 英文别名: 5-Chloro-2-fluoro-1-methoxy-3-(methylsulfinyl)benzene；5-chloro-2-fluoro-1-methoxy-3-methylsulfinylbenzene
• CAS: 1452479-03-6
• 化学式: C₈H₈ClFO₂S
• 分子量: 222.668
• InChiKey: YHUIPQNXAVGZOD-UHFFFAOYSA-N

物化性质

• 沸点：
  369.1±42.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-chloro-2-fluoro-1-methoxy-3-(methylsulfinyl)benzene 在 甲烷磺酸 、 potassium carbonate 、 三氟乙酸酐 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 5.25h， 生成 methyl (4-chloro-7-fluoro-6-methoxy-1-benzothiophen-3-yl)acetate
  参考文献：
  名称：

  [EN] AROMATIC RING COMPOUND
  [FR] COMPOSÉ À NOYAU AROMATIQUE

  摘要：

  本发明提供了一种具有GOAT抑制作用的化合物，该化合物用于预防或治疗肥胖等疾病，并具有优异的疗效。本发明的化合物由式(I)表示：其中每个符号如说明书中所定义，或其盐。

  公开号：

  WO2013125732A1
• 作为产物：
  描述：

  4-氯-1-氟-2-甲氧基苯 在 sodium periodate 、 仲丁基锂 作用下， 以 四氢呋喃 、 甲醇 、 环己烷 、 水 为溶剂， 反应 26.75h， 生成 5-chloro-2-fluoro-1-methoxy-3-(methylsulfinyl)benzene
  参考文献：
  名称：

  [EN] AROMATIC RING COMPOUND
  [FR] COMPOSÉ À NOYAU AROMATIQUE

  摘要：

  本发明提供了一种具有GOAT抑制作用的化合物，该化合物用于预防或治疗肥胖等疾病，并具有优异的疗效。本发明的化合物由式(I)表示：其中每个符号如说明书中所定义，或其盐。

  公开号：

  WO2013125732A1

文献信息

• AROMATIC RING COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150018547A1

  公开（公告）日：2015-01-15

  The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有GOAT抑制作用的化合物，该化合物可用于预防或治疗肥胖等疾病，并具有优越的疗效。该化合物由式(I)表示，其中每个符号如规范中所定义，或其盐。
• Aromatic ring compound
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US09238639B2

  公开（公告）日：2016-01-19

  The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供一种具有GOAT抑制作用的化合物，可用于预防或治疗肥胖等疾病，并具有优异的功效。本发明是由式（I）表示的化合物：其中每个符号如规范中所定义，或其盐。
• Ghrelin O-acyltransferase inhibitors
  申请人：Glaxosmithkline Intellectual Property Development Limited

  公开号：US11312709B2

  公开（公告）日：2022-04-26

  This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g., alcohol, smoking, overeating, or use of illicit drugs))), as well as disorders related to or complications of metabolic or psychiatric disorders (e.g., cardiovascular diseases (e.g., diabetic heart disease (e.g., diabetic cardiomyopathy), heart failure, or hypertension), ischemia (e.g., myocardial ischemia, cerebral ischemia, ischemic stroke), or BMI-related cancers (e.g., pancreatic cancer, gallbladder cancer, esophageal cancer, colorectal cancer, breast cancer etc.).

  本发明涉及作为胃泌素O-酰基转移酶(GOAT)抑制剂的符合式(I)的新型化合物，涉及含有它们的药物组合物，涉及它们的制备工艺，涉及它们在治疗代谢紊乱（例如，普拉德-威利综合征、代谢综合征、胰岛素抵抗、糖耐量受损、糖尿病前期、糖尿病（例如、胰岛素抵抗、糖耐量受损、糖尿病前期、糖尿病（如 II 型糖尿病）、血糖异常（如高血糖）、肥胖（如由普拉德-威利综合征引起的肥胖）、脂肪增加、血糖控制不良、食欲亢进、饱腹感受损、血脂异常（如致动脉粥样硬化性血脂异常）、肝脂肪变性（如非酒精性脂肪肝（如非酒精性脂肪性肝炎））、精神障碍（如进食障碍（如神经性贪食症、暴饮暴食症、夜食综合征）、药物相关障碍（如成瘾障碍（如酗酒、吸烟、暴饮暴食或使用违禁药物））），以及与代谢或精神障碍相关的疾病或并发症（如心血管疾病（如糖尿病性心脏病（如糖尿病性心肌病）、心力衰竭或高血压）、缺血（如心肌缺血、脑缺血、缺血性中风）或与 BMI 有关的癌症（如胰腺癌、胆囊癌、食道癌、结肠直肠癌、乳腺癌等）。
• AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2838891B1

  公开（公告）日：2017-08-02
• GHRELIN O-ACYLTRANSFERASE INHIBITORS
  申请人：Glaxosmithkline Intellectual Property Development Limited

  公开号：US20210053955A1

  公开（公告）日：2021-02-25

  This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g., alcohol, smoking, overeating, or use of illicit drugs))), as well as disorders related to or complications of metabolic or psychiatric disorders (e.g., cardiovascular diseases (e.g., diabetic heart disease (e.g., diabetic cardiomyopathy), heart failure, or hypertension), ischemia (e.g., myocardial ischemia, cerebral ischemia, ischemic stroke), or BMI-related cancers (e.g., pancreatic cancer, gallbladder cancer, esophageal cancer, colorectal cancer, breast cancer etc.).